RESULTS ANNOUNCED FOR TRIAL OF INFLAMMATORY ARTHRITIS TREATMENT
Targeted Genetics announced that the preliminary results from its Phase I clinical
trial of tgAAC94 in patients with inflammatory arthritis demonstrate that the
experimental drug is well-tolerated and can be safely administered directly
into joints of patients with inflammatory arthritis. Preliminary data suggest
improvements in signs and symptoms of arthritis in the treated joints.
The trial, conducted in the U.S. and Canada, was a multicenter trial of tgAAC94
injected locally into the arthritic joint. Fifteen patients who enrolled in
the trial were randomized to receive either one of two escalating dose levels
of tgAAC94 or a placebo. The trial contained a placebo arm at each dose level,
which was included primarily to assess whether any adverse events that might
be seen were attributable to an intra-articular injection itself, as opposed
to an intra-articular injection of tgAAC94.
The trial has now been closed for enrollment and patients will continue to be
followed for 24 weeks after injection.
Upcoming Events
-
21Oct